Responses to Common Misconceptions Relating to COVID-19 Variant-Adapted mRNA Vaccines.

Responses to Common Misconceptions Relating to COVID-19 Variant-Adapted mRNA Vaccines.

Publication date: Jan 06, 2024

The evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the waning of immunity over time has necessitated the use of booster doses of original coronavirus disease 2019 (COVID-19) vaccines. This has also led to the development and implementation of variant-adapted messenger RNA (mRNA) vaccines that include an Omicron sub-lineage component in addition to the antigen based on the wild-type virus spike protein. Subsequent emergence of the recombinant XBB sub-lineages triggered the development of monovalent XBB-based variant-adapted mRNA vaccines, which are available for vaccination campaigns in late 2023. Misconceptions about new variant-adapted vaccines may exacerbate vaccine fatigue and drive the lack of vaccine acceptance. This article aims to address common concerns about the development and use of COVID-19 variant-adapted mRNA vaccines that have emerged as SARS-CoV-2 has continued to evolve.

Open Access PDF

Concepts Keywords
Basel BNT162b2
Coronavirus COVID-19
Fatigue mRNA vaccines
Recombinant SARS-CoV-2
Vaccination SARS-CoV-2 Omicron variant
vaccination hesitancy

Semantics

Type Source Name
disease MESH COVID-19
disease VO Severe acute respiratory syndrome coronavirus 2
disease VO time
disease VO vaccination
disease VO vaccine
disease VO LACK
drug DRUGBANK Coenzyme M
disease MESH Infection
disease VO organization
disease VO effectiveness
disease MESH myocarditis
disease VO population
disease IDO process
disease MESH influenza
disease VO vaccinated
disease MESH ischemic stroke
disease VO Optaflu
disease VO influenza vaccines
disease MESH death
disease VO unvaccinated
disease VO dose
disease MESH re infection
disease MESH Breakthrough infections
disease VO primary vaccination
disease IDO cell
drug DRUGBANK Serine
drug DRUGBANK Cyclic Adenosine Monophosphate
disease VO vaccine efficacy
disease VO USA
disease VO Viruses
disease MESH mutation rates
drug DRUGBANK Tropicamide
disease VO vaccine effectiveness
disease MESH emergency
disease IDO susceptibility
disease MESH sequelae
disease MESH ‘long COVID
disease IDO symptom
disease VO effective
drug DRUGBANK Methionine
disease VO regulatory agency
disease IDO quality
disease IDO history
disease IDO country
disease MESH pediatric inflammatory multisystem syndrome
disease VO frequency
disease IDO production
disease MESH critical illness
disease MESH febrile seizures
drug DRUGBANK Tretamine
disease MESH syndrome
disease MESH pericarditis
disease IDO blood
disease VO vaccine adverse event
disease VO pregnant women
disease MESH pregnancy outcomes
disease MESH stillbirth
disease MESH premature birth
disease MESH fetal death
disease VO adverse event
disease VO volume
disease MESH infectious diseases
disease VO vaccine dose
disease MESH viral infection
pathway KEGG Viral myocarditis
disease MESH abnormalities
drug DRUGBANK Gadolinium
disease MESH stroke
drug DRUGBANK Pentaerythritol tetranitrate
disease VO document
disease MESH Heart Failure
drug DRUGBANK Guanosine
drug DRUGBANK Carboxyamidotriazole
disease VO Comirnaty
disease MESH respiratory infections
disease VO report
pathway KEGG Coronavirus disease
disease MESH immunocompromised patients
disease MESH cancer
pathway REACTOME Release
disease MESH Birth Defects
disease IDO primary infection
disease MESH Seizure
drug DRUGBANK (S)-Des-Me-Ampa
disease VO coronavirus vaccine
disease VO immunization
disease VO protocol
disease MESH Myocardial Infarction
disease MESH Pulmonary Embolism

Original Article

(Visited 1 times, 1 visits today)